A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With That of a Licensed Meningococcal ACWY Polysaccharide Vaccine (Menomune) Administered to Healthy Children 2 to 10 Years of Age

Trial Profile

A Phase 3, Randomized, Observer-blind, Controlled, Multi-Center Study to Compare the Safety of One Dose of Novartis Meningococcal ACWY Conjugate Vaccine With That of a Licensed Meningococcal ACWY Polysaccharide Vaccine (Menomune) Administered to Healthy Children 2 to 10 Years of Age

Completed
Phase of Trial: Phase III

Latest Information Update: 04 Nov 2013

At a glance

  • Drugs Meningococcal vaccine groups A C Y W-135 conjugate; Meningococcal vaccine groups A C Y W-135 polysaccharide
  • Indications Meningococcal group A infections; Meningococcal group C infections; Meningococcal group W-135 infections; Meningococcal group Y infections
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Chiron Corporation; Novartis
  • Most Recent Events

    • 02 Mar 2012 Actual end date (May 2007) added as reported by ClinicalTrials.gov.
    • 02 Mar 2012 Company (Novartis Vaccines) added as trial sponsor as reported by ClinicalTrials.gov.
    • 16 Apr 2008 Status changed from in progress to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top